Pluri Inc.
PLURNasdaq
$1.86
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↓ -63.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$18.7M
Enterprise Value
$15.3M
P/E
—
P/S
17.3
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-116.0%
Dividend Yield
—
Revenue (TTM)
$1.1M
Net Income (TTM)
$20.3M
Free Cash Flow (TTM)
-$21.7M
Gross Margin
43.0%
Operating Margin
-2410.8%
Net Margin
1880.8%
ROE
-109.1%
ROIC
—
Debt / Equity
—
Net Cash
$3.4M
Return 1Y
-65.6%
Company profile
Pluristem Therapeutics Inc. focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture.
- CEO
- Yaky Yanay
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Website
- pluri-biotech.com
Management & directors
- Yanay YakyChief Executive Officer
- Zalts LiatChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
PLUR Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$167,000.00↓ -60.9%
Diluted EPS-$0.55↓ -41.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $234,000.00 | $287,000.00 | $326,000.00 | $1.3M |
| Gross profit | — | $234,000.00 | $278,000.00 | $322,000.00 | $654,000.00 |
| Operating income | -$50.6M | -$41.6M | -$27.2M | -$22.2M | -$22.2M |
| Net income | -$49.9M | -$41.2M | $28.9M | $21.3M | $23.3M |
| Diluted EPS | -$1.77 | -$1.28 | -$6.24 | -$3.99 | -$3.56 |
| Operating cash flow | -$30.9M | -$36.5M | -$22.9M | -$18.0M | -$18.2M |
| Free cash flow | -$31.3M | -$36.8M | -$23.1M | -$18.3M | -$19.8M |
| Gross margin | — | 100.0% | 96.9% | 98.8% | 49.0% |
| Operating margin | — | -17774.8% | -9493.4% | -6796.9% | -1659.9% |
| Net margin | — | -17624.8% | 10065.2% | 6547.2% | 1740.3% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $96,000.00 | $326,000.00 | $185,000.00 | $427,000.00 | $398,000.00 | $316,000.00 | $198,000.00 | $167,000.00 |
| Gross profit | $92,000.00 | $200,000.00 | $111,000.00 | $136,000.00 | $207,000.00 | $115,000.00 | $86,000.00 | $56,000.00 |
| Operating income | -$6.0M | -$5.2M | -$5.0M | -$5.4M | -$6.6M | -$6.3M | -$6.5M | -$6.5M |
| Net income | $36.5M | -$5.9M | -$3.0M | -$6.1M | $38.2M | -$5.8M | -$6.5M | -$5.5M |
| Diluted EPS | -$1.06 | -$1.08 | -$0.53 | -$0.94 | -$1.01 | -$0.65 | -$0.71 | -$0.55 |
| Operating cash flow | -$4.3M | -$4.1M | -$4.6M | -$4.3M | -$5.2M | -$5.4M | -$5.2M | -$4.5M |
| Free cash flow | -$4.3M | -$4.3M | -$4.7M | -$4.9M | -$5.9M | -$5.5M | -$5.7M | -$4.6M |
| Gross margin | 95.8% | 61.3% | 60.0% | 31.9% | 52.0% | 36.4% | 43.4% | 33.5% |
| Operating margin | -6285.4% | -1594.5% | -2679.5% | -1264.6% | -1663.6% | -2009.5% | -3285.9% | -3913.8% |
| Net margin | 38024.0% | -1804.3% | -1597.8% | -1439.6% | 9606.8% | -1851.3% | -3304.5% | -3322.2% |
Company news
May 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Manieu Alexandre Weinstein | Award | 641 | $0.00 | $0.00 | filing |
| 2026-04-21 | Manieu Alexandre Weinstein | Award | 312,500 | $2.00 | $625,000.00 | filing |
| 2026-03-31 | Manieu Alexandre Weinstein | Award | 312,500 | $2.00 | $625,000.00 | filing |
| 2025-12-08 | Manieu Alexandre Weinstein | Award | 625,000 | $2.00 | $1.3M | filing |
| 2025-12-04 | Manieu Alexandre Weinstein | Award | 519 | $0.00 | $0.00 | filing |
| 2025-12-04 | Ajchenbaum Eitan | Award | 668 | $0.00 | $0.00 | filing |
| 2025-12-04 | YANAY YAKY· Chief Executive Officer | Award | 6,588 | $0.00 | $0.00 | filing |
| 2025-12-04 | Levi Rami Avraham | Award | 653 | $0.00 | $0.00 | filing |
| 2025-12-04 | Zalts Liat· Chief Financial Officer | Award | 3,660 | $0.00 | $0.00 | filing |
| 2025-12-04 | Shemesh-Rasmussen Maital | Award | 699 | $0.00 | $0.00 | filing |
| 2025-12-04 | Aberman Zami | Award | 346 | $0.00 | $0.00 | filing |
| 2025-11-12 | Ajchenbaum Eitan | Award | 11,685 | $0.00 | $0.00 | filing |
| 2025-10-29 | Manieu Alexandre Weinstein | Option exercise | 1,002,169 | $0.00 | $100.22 | filing |
| 2025-10-15 | YANAY YAKY· Chief Executive Officer | Award | 39,050 | $0.00 | $0.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.